- Home
- TTNP vs XRTX Comparison
TTNP vs XRTX Comparison
Compare TTNP & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- XRTX
- Stock Information
- Founded
- TTNP 1991
- XRTX 2011
- Country
- TTNP United States
- XRTX Canada
- Employees
- TTNP N/A
- XRTX N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- XRTX Pharmaceuticals and Biotechnology
- Sector
- TTNP Health Care
- XRTX Health Care
- Exchange
- TTNP Nasdaq
- XRTX Nasdaq
- Market Cap
- TTNP 3.0M
- XRTX 3.0M
- IPO Year
- TTNP 1996
- XRTX N/A
- Fundamental
- Price
- TTNP $3.67
- XRTX $0.82
- Analyst Decision
- TTNP
- XRTX
- Analyst Count
- TTNP 0
- XRTX 0
- Target Price
- TTNP N/A
- XRTX N/A
- AVG Volume (30 Days)
- TTNP 25.0K
- XRTX 45.7K
- Earning Date
- TTNP 03-31-2025
- XRTX 11-15-2024
- Dividend Yield
- TTNP N/A
- XRTX N/A
- EPS Growth
- TTNP N/A
- XRTX N/A
- EPS
- TTNP N/A
- XRTX N/A
- Revenue
- TTNP N/A
- XRTX N/A
- Revenue This Year
- TTNP N/A
- XRTX N/A
- Revenue Next Year
- TTNP N/A
- XRTX N/A
- P/E Ratio
- TTNP N/A
- XRTX N/A
- Revenue Growth
- TTNP N/A
- XRTX N/A
- 52 Week Low
- TTNP $3.03
- XRTX $0.82
- 52 Week High
- TTNP $14.80
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- TTNP 50.98
- XRTX 34.99
- Support Level
- TTNP $3.35
- XRTX $0.87
- Resistance Level
- TTNP $4.24
- XRTX $0.97
- Average True Range (ATR)
- TTNP 0.29
- XRTX 0.07
- MACD
- TTNP 0.02
- XRTX 0.00
- Stochastic Oscillator
- TTNP 46.73
- XRTX 0.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.